Core Insights - Burcon Nutrascience Corporation has made significant advancements in commercialization, achieving first commercial production and sales of Puratein® C canola protein and FavaPro fava protein in Q2 FY26 [1][7] - The company recorded revenues of $0.36 million in Q2 FY26, representing a 783% increase compared to the same period last year, driven by initial protein sales and contract manufacturing [7] - Burcon received over $500,000 in commercial sales orders after the quarter-end, indicating growing demand as customers transition from evaluations to purchase orders [1][7] Company Developments - The Galesburg facility has successfully initiated commercial production of multiple proteins, including Puratein® C and FavaPro, while scaling Peazazz® C pea protein [1] - The company has strengthened its financing through up to $4.0 million in unsecured convertible debentures and a $0.7 million short-term loan, with at least $2.0 million of insider participation [7] - Operational flexibility allows Burcon to quickly meet evolving customer needs with consistent quality [1]

Core Insights - Burcon NutraScience Corporation reported strong operational execution and growing commercial traction in the plant-based protein sector, reaffirming its revenue targets for 2025 and 2026 [2][3][6] Operational Highlights - Burcon has over 200 active customer projects, with many nearing completion, indicating a rapid scaling of demand and transition to recurring commercial sales [4] - The company successfully commercialized its technology for canola and fava protein production at its Galesburg facility [3] - Recent production runs have been allocated to innovative food and beverage companies, showcasing broad customer adoption [5] Financial Performance - For the fiscal second quarter ended September 30, 2025, Burcon generated revenues of $357,000, representing a 783% increase year-over-year [7] - The company reported a net loss of $7.1 million, compared to a loss of $4.2 million in the same period last year, driven by increased costs associated with production [9] - Cash used in operating activities increased to $4.6 million from $3.0 million in the prior year [9] Future Outlook - Burcon aims to achieve a revenue target of over $10 million for calendar 2026, supported by strong market validation and a diversified protein portfolio [6] - The company is focused on strengthening customer partnerships and scaling production to meet global demand [6] Financial Position - As of September 30, 2025, Burcon had $1.8 million in cash and a negative working capital of $8.2 million, primarily due to a senior secured loan from a related party [10] - The company has taken steps to improve its financial position, including obtaining a $0.7 million short-term loan and launching a convertible debenture offering for up to $4 million [10]

Core Viewpoint - Burcon NutraScience Corporation is set to showcase its innovative Chipotle Black Bean Protein Hummus at the IFT FIRST Annual Event & Expo, highlighting its advancements in plant-based protein technology [1][6]. Group 1: Product Innovation - The Chipotle Black Bean Protein Hummus is crafted using Burcon's proprietary triple blend of Peazazz®C pea protein, Puratein®C canola protein, and Solatein™ sunflower protein, resulting in a dip that is both flavorful and nutritious [6][8]. - Burcon's plant-based proteins boast over 90% purity, neutral flavor, and smooth mouthfeel, making them suitable for various food applications [6][9]. Group 2: Event Details - The IFT FIRST event will take place in Chicago from July 13-16, 2025, where Burcon will be located at booth S4066 [1][6]. - Attendees will have the opportunity to sample the Chipotle Black Bean Protein Hummus during a special tasting event on July 14 and 15, from 11:00 AM to 1:00 PM [7][9]. Group 3: Company Background - Burcon NutraScience is recognized as a global leader in high-performance plant-based proteins, with a strong commitment to sustainability and innovation in the food and beverage industry [11]. - The company holds an extensive patent portfolio covering novel proteins derived from various plant sources, positioning itself as a key player in the growing plant-based market [11].